Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RGC
RGC logo

RGC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.550
Open
24.180
VWAP
24.05
Vol
71.43K
Mkt Cap
11.84B
Low
23.710
Amount
1.72M
EV/EBITDA(TTM)
--
Total Shares
495.47M
EV
11.94B
EV/OCF(TTM)
--
P/S(TTM)
--
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Show More

Events Timeline

(ET)
2026-04-07
12:10:00
Regencell Bioscience Shares Down 10.7% to $27.52
select
2026-04-07
10:10:00
Regencell Bioscience Shares Down 7.1% to $28.64
select
2026-04-02 (ET)
2026-04-02
12:10:00
Regencell Bioscience Shares Down 9.5% to $30.50
select
2026-04-01 (ET)
2026-04-01
12:10:00
Regencell Bioscience Stock Rises 49.5% to $38.02
select
2026-04-01
10:10:00
Regencell Bioscience Stock Rises 23.9% to $31.50
select
2026-03-30 (ET)
2026-03-30
06:20:00
Regencell Bioscience Files to Sell Ordinary Shares
select
2026-03-23 (ET)
2026-03-23
12:10:00
Regencell Bioscience Shares Down 8.7% to $25.00
select
2026-03-18 (ET)
2026-03-18
12:10:00
Regencell Bioscience Stock Rises 15.4% to $26.50
select
2026-03-18
10:10:00
Regencell Bioscience Stock Rises 26.7% to $29.11
select

News

Globenewswire
7.0
05-29Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
  • Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
  • Allegations of False Statements: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
  • Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of protecting the rights of affected investors in this case.
  • Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, offering no-cost legal consultations to help investors understand their rights and options regarding the lawsuit.
PRnewswire
7.0
05-28PRnewswire
Regencell Securities Class Action Notice
  • Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
  • Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and significant financial risks, potentially leading to legal and reputational harm.
  • Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
  • Investor Rights Protection: Investors can participate in the lawsuit without any out-of-pocket fees through Rosen Law Firm, ensuring their rights are protected in any potential future recovery.
Globenewswire
7.0
05-28Globenewswire
Regencell Investors Reminded of Class Action Deadline
  • Lawsuit Background: Regencell Bioscience Holdings Limited is facing a class action lawsuit for failing to disclose market manipulation risks during the period from October 28, 2024, to October 31, 2025, with investors able to file as lead plaintiffs by June 23, 2026, to seek compensation.
  • Legal Investigation: On October 31, 2025, Regencell revealed it received a subpoena from the U.S. Department of Justice indicating an investigation into its ordinary share trading, with expectations of incurring significant legal costs and potential fines, exacerbating financial risks for investors.
  • Stock Price Volatility: Following the investigation announcement, Regencell's stock price fell by $3.09, or 18.56%, on November 3, 2025, directly causing investor losses and reflecting a crisis of market trust in the company.
  • Disclosure Failures: The lawsuit alleges that throughout the class period, the company failed to disclose significant financial and legal risks, leading investors to hold an overly optimistic view of the company's prospects, which may trigger broader regulatory scrutiny.
Globenewswire
7.0
05-28Globenewswire
Regencell Securities Class Action Reminder
  • Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action without any out-of-pocket fees.
  • Legal Risks Exposed: The lawsuit alleges that Regencell made false and misleading statements during the Class Period, exposing investors to market manipulation risks and significant financial losses, which could lead to regulatory scrutiny and legal repercussions.
  • Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
  • Investor Advisory: Investors are advised to carefully select legal counsel and avoid inexperienced intermediaries to ensure effective legal support and representation in the class action.
Globenewswire
7.0
05-27Globenewswire
Multiple Companies Face Class Action Lawsuits
  • LKQ Corporation Lawsuit: LKQ faces a class action lawsuit for the period from February 27, 2023, to July 23, 2025, alleging that executives failed to disclose significant risks regarding customer losses and market share erosion, misleading investors and negatively impacting the company's reputation and stock price.
  • Regencell Bioscience Lawsuit: During the class period from October 28, 2024, to October 31, 2025, Regencell is accused of not disclosing risks of market manipulation and financial exposure, which could lead to legal and reputational harm, increasing investor anxiety.
  • Globant Lawsuit: Globant is facing a class action for the period from February 15, 2024, to August 14, 2025, due to failure to disclose decreasing demand in Latin America and wage freezes, severely undermining investor confidence in the company's prospects.
  • Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights.
Globenewswire
7.0
05-25Globenewswire
Regencell Securities Class Action Reminder
  • Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
  • Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the litigation.
  • Legal Risk Disclosure: The lawsuit alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks, and the revelation of this information could lead to further declines in the company's stock price, impacting investor confidence.
  • Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases, prompting investors to carefully select legal counsel to protect their rights.

Valuation Metrics

The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regencell Bioscience Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

ARE QUANTUM STOCKS GOING DOWN
Intellectia · 29 candidates
Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceBelowMA20, PriceBelowMA200Month Price Change Pct: <= $0.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000Macd: bearish
Ticker
Name
Market Cap$
top bottom
WOK logo
WOK
WORK Medical Technology Group Ltd
191.43K
LICN logo
LICN
Lichen International Ltd
17.75M
ZEPP logo
ZEPP
Zepp Health Corp
129.05M
FUTU logo
FUTU
Futu Holdings Ltd
15.10B
TIGR logo
TIGR
UP Fintech Holding Ltd
894.39M
CRBP logo
CRBP
Corbus Pharmaceuticals Holdings Inc
210.29M
okay give me some I can buy
Intellectia · 8 candidates
Market Cap: >= 10.00BRegion: USPrice: $5.00 - $60.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $20.00Monthly Average Dollar Volume: >= 5,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
11.85B
AMKR logo
AMKR
Amkor Technology Inc
13.66B
SKM logo
SKM
SK Telecom Co Ltd
13.67B
SBS logo
SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
23.76B
STLA logo
STLA
Stellantis NV
29.78B
RGC logo
RGC
Regencell Bioscience Holdings Ltd
13.93B
stick of the week
Intellectia · 10 candidates
Market Cap: >= 10.00BRsi Category: moderateMoving Average Relationship: PriceAboveMA200Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
12.12B
SBAC logo
SBAC
SBA Communications Corp
22.64B
INTC logo
INTC
Intel Corp
254.58B
STX logo
STX
Seagate Technology Holdings PLC
96.19B
CIEN logo
CIEN
Ciena Corp
61.40B
LITE logo
LITE
Lumentum Holdings Inc
55.14B
what should I buy for swing trading
Intellectia · 426 candidates
Price: $10.00 - $150.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MLEC logo
MLEC
Moolec Science SA
5.05M
AEHR logo
AEHR
Aehr Test Systems
1.36B
BKSY logo
BKSY
Blacksky Technology Inc
1.14B
LUNR logo
LUNR
Intuitive Machines Inc
5.20B
KRRO logo
KRRO
Korro Bio Inc
201.92M
SNSE logo
SNSE
Sensei Biotherapeutics Inc
41.58M
top moving stocks
Intellectia · 31 candidates
Market Cap: >= 500.00MPrice: >= $2.00Price Change Pct: $-100.00 - $-5.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
LNN logo
LNN
Lindsay Corp
1.22B
KNF logo
KNF
Knife River Corp
4.65B
OMER logo
OMER
Omeros Corp
869.71M
WIX logo
WIX
Wix.Com Ltd
5.28B
IRWD logo
IRWD
Ironwood Pharmaceuticals Inc
635.93M
PBH logo
PBH
Prestige Consumer Healthcare Inc
2.73B
stocks gain $5.00 in 2026
Intellectia · 2622 candidates
Year Price Change Pct: >= $0.01
Ticker
Name
Market Cap$
top bottom
AXTI logo
AXTI
AXT Inc
3.80B
PTN logo
PTN
Palatin Technologies Inc
35.18M
RGC logo
RGC
Regencell Bioscience Holdings Ltd
12.08B
RLMD logo
RLMD
Relmada Therapeutics Inc
639.83M
BW logo
BW
Babcock & Wilcox Enterprises Inc
1.95B
TERN logo
TERN
Terns Pharmaceuticals Inc
5.44B
bullish stocks this week
Intellectia · 56 candidates
Market Cap: >= 4.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MASI logo
MASI
Masimo Corp
9.43B
IBRX logo
IBRX
Immunitybio Inc
8.41B
ONDS logo
ONDS
Ondas Inc
4.98B
MRNA logo
MRNA
Moderna Inc
18.21B
ELF logo
ELF
elf Beauty Inc
5.20B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
17.84B
ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي
Intellectia · 1346 candidates
Year Price Change Pct: >= $25.00
Ticker
Name
Market Cap$
top bottom
RGC logo
RGC
Regencell Bioscience Holdings Ltd
13.54B
PTN logo
PTN
Palatin Technologies Inc
28.78M
ANPA logo
ANPA
Rich Sparkle Holdings Ltd
875.38M
ABVX logo
ABVX
Abivax SA
8.86B
SNDK logo
SNDK
Sandisk Corp
97.55B
HYMC logo
HYMC
Hycroft Mining Holding Corporation
3.20B
what’s a good buy for day trading
Intellectia · 2418 candidates
Region: USPrice: $2.00 - $200.00Volume: >= 200,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
AZN logo
AZN
AstraZeneca PLC
298.35B
PLAG logo
PLAG
Planet Green Holdings Corp
30.35M
AQST logo
AQST
Aquestive Therapeutics Inc
509.36M
CATX logo
CATX
Perspective Therapeutics Inc
351.47M
ASTI logo
ASTI
Ascent Solar Technologies Inc
29.36M
PAVM logo
PAVM
PAVmed Inc
9.16M
entonces que acciones?
Intellectia · 74 candidates
Market Cap: >= 3.00BRsi Category: moderateWeek Price Change Pct: $5.00 - $20.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SSL logo
SSL
Sasol Ltd
4.76B
LMND logo
LMND
Lemonade Inc
6.97B
TEO logo
TEO
Telecom Argentina SA
5.50B
SBS logo
SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
18.55B
KEP logo
KEP
Korea Electric Power Corp
27.73B
PKX logo
PKX
Posco Holdings Inc
19.18B

Whales Holding RGC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Regencell Bioscience Holdings Ltd (RGC) stock price today?

The current price of RGC is 23.9 USD — it has decreased -0.87

What is Regencell Bioscience Holdings Ltd (RGC)'s business?

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

What is the price predicton of RGC Stock?

Wall Street analysts forecast RGC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regencell Bioscience Holdings Ltd (RGC)'s revenue for the last quarter?

Regencell Bioscience Holdings Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Regencell Bioscience Holdings Ltd (RGC)'s earnings per share (EPS) for the last quarter?

Regencell Bioscience Holdings Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Regencell Bioscience Holdings Ltd (RGC). have?

Regencell Bioscience Holdings Ltd (RGC) has 10 emplpoyees as of May 31 2026.

What is Regencell Bioscience Holdings Ltd (RGC) market cap?

Today RGC has the market capitalization of 11.84B USD.